BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 34681905)

  • 1. Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications.
    Biagetti B; Simò R
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
    Shimon I
    Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment of prolactin-secreting macroadenomas with pergolide.
    Freda PU; Andreadis CI; Khandji AG; Khoury M; Bruce JN; Jacobs TP; Wardlaw SL
    J Clin Endocrinol Metab; 2000 Jan; 85(1):8-13. PubMed ID: 10634356
    [No Abstract]   [Full Text] [Related]  

  • 4. Non-surgical management of cystic prolactinomas.
    Bahuleyan B; Menon G; Nair S; Rao BR; Easwer HV; Krishna K
    J Clin Neurosci; 2009 Nov; 16(11):1421-4. PubMed ID: 19699096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment.
    Oguz A; Tuzun D; Sahin M; Gul K
    Niger J Clin Pract; 2016; 19(5):685-7. PubMed ID: 27538562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistant prolactinomas.
    Vasilev V; Daly AF; Vroonen L; Zacharieva S; Beckers A
    J Endocrinol Invest; 2011 Apr; 34(4):312-6. PubMed ID: 21406957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of prolactinomas during pregnancy.
    Witek P; Zieliński G
    Minerva Endocrinol; 2013 Dec; 38(4):351-63. PubMed ID: 24285103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.
    Cooper O; Mamelak A; Bannykh S; Carmichael J; Bonert V; Lim S; Cook-Wiens G; Ben-Shlomo A
    Endocrine; 2014 Jun; 46(2):318-27. PubMed ID: 24287797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
    Burlacu MC; Maiter D; Duprez T; Delgrange E
    Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucocele-like formation leading to neurological symptoms in prolactin-secreting pituitary adenomas under dopamine agonist therapy.
    Abe T; Lüdecke DK
    Surg Neurol; 1999 Sep; 52(3):274-9. PubMed ID: 10511086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary gland: can prolactinomas be cured medically?
    Molitch ME
    Nat Rev Endocrinol; 2010 Apr; 6(4):186-8. PubMed ID: 20336161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine agonist therapy in prolactinomas: when can treatment be discontinued?
    Klibanski A
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2247-9. PubMed ID: 19584197
    [No Abstract]   [Full Text] [Related]  

  • 13. Prolactin, prolactin disorders, and dopamine agonists during pregnancy.
    Levin G; Rottenstreich A
    Hormones (Athens); 2019 Jun; 18(2):137-139. PubMed ID: 30341577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Giant prolactinomas: Multi-modal approach to achieve tumor control.
    Shimon I
    Endocrine; 2017 May; 56(2):227-228. PubMed ID: 28050685
    [No Abstract]   [Full Text] [Related]  

  • 15. When to discontinue treatment of prolactinoma?
    Wass JA
    Nat Clin Pract Endocrinol Metab; 2006 Jun; 2(6):298-9. PubMed ID: 16932302
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.
    Yang A; Cho SY; Park H; Kim MS; Kong DS; Shin HJ; Jin DK
    Front Endocrinol (Lausanne); 2020; 11():527. PubMed ID: 32849307
    [No Abstract]   [Full Text] [Related]  

  • 17. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine agonist-resistant prolactinomas.
    Oh MC; Aghi MK
    J Neurosurg; 2011 May; 114(5):1369-79. PubMed ID: 21214334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recurrence of prolactinoma surveyed. Hormone therapy can safely be withdrawn for a long time in patients with normalized prolactin levels and invisible tumor].
    Werner S
    Lakartidningen; 2004 Oct; 101(41):3162-3. PubMed ID: 15517713
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperprolactinemia and prolactinoma.
    Romijn JA
    Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.